Incidence and Consistency of Antiretroviral Use Among HIV-Infected Medicaid Beneficiaries With Schizophrenia
J Clin Psychiatry 2001;62(3):174-178
© Copyright 2016 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: To investigate the incidence and
consistency of antiretroviral (ARV) treatment in the period
before the introduction of protease inhibitors among Medicaid
beneficiaries in New Jersey who had both the human
immunodeficiency virus (HIV) and schizophrenia.
Method: HIV-infected Medicaid beneficiaries were
identified using the HIV and acquired immunodeficiency syndrome
(AIDS) registries for New Jersey; claims histories were used to
identify patients diagnosed with ICD-9-CM schizophrenia and
affective psychoses and to examine use of ARV drugs.
Results: Bivariate and multivariate analysis
found no difference in the likelihood of receiving ARV drugs
between patients with HIV and schizophrenia and HIV-infected
patients without schizophrenia. However, once the therapy was
initiated, patients with schizophrenia were more consistent users
of ARV drugs.
Conclusion: Results do not indicate that
HIV-seropositive (HIV+) patients with schizophrenia are less
adherent to HIV therapies than HIV+ patients without
schizophrenia. In our study population, consistency of use was
actually higher among HIV+ patients with schizophrenia, perhaps
because their multiple diagnoses place them under closer medical